Infections of the Central Nervous System, 4th Ed.

Chapter 7. Poliomyelitis, Polio Vaccines, and the Postpoliomyelitis Syndrome

JOHN F. MODLIN AND DAVID J. COFFEY

Poliomyelitis is a systemic viral infection caused by any of three human poliovirus serotypes that is characterized by acute meningitis and lytic infection of motor neurons in the brainstem and spinal cord resulting in cranial nerve dysfunction and transient or permanent paresis of one or more extremities. In the United States and other developed countries, poliomyelitis due to naturally occurring polioviruses has been eliminated by routine childhood immunization. Global eradication is a major priority of the World Health Organization (WHO) and other major partners in the Global Poliomyelitis Eradication Initiative.

A BRIEF HISTORY OF POLIOMYELITIS

Poliomyelitis has afflicted humans since antiquity (1). The first acknowledged description in English is a biographical narrative of the acute paralysis suffered by Sir Walter Scott in the second year of his life, circa 1772, and the first medical description is recorded in the second edition of A Treatise on Diseases of Children, published in 1789 by Michael Underwood, a London pediatrician and obstetrician (2,3). Major contributions to understanding the disease were made by the German orthopedist Heine, whose 1840 monograph describes the clinical features of acute poliomyelitis in young children (4), by the French anatomist Charcot who showed that paralysis was accompanied by a loss of motor nerve cells within the anterior horns of the cord (5), and by Karl Oskar Medin, a Swedish pediatrician who, in 1887, recorded the natural history of poliomyelitis and developed a classification that became widely used for decades afterwards. The eponym “Heine-Medin disease” was widely used throughout Europe and North America during the early twentieth century.

Up to this time, only sporadic cases of poliomyelitis were recognized. The first recorded outbreaks of poliomyelitis occurred in the mid- and late nineteenth century in northern Europe and later in North America. Charles Caverly, a Dartmouth College trained physician, described 132 cases with 18 deaths in the Otter Creek Valley near Rutland, Vermont, the largest outbreak known to have occurred up to that time in North America (6). These early outbreaks heralded larger epidemics, including a countrywide epidemic of more than 1,000 cases in Sweden in 1905 (7) and 1,200 cases in New York City in 1907 (1), and the spread of disease throughout Europe and North America. The shift from endemic to epidemic disease has been ascribed to the improved hygienic conditions that accompanied the increasing standards of living in the industrialized world. In theory, extensive exposure to polioviruses during infancy in the presence of passively acquired maternal antibody results in harmless but immunizing infections. Conversely, infections delayed beyond infancy as a result of higher sanitary standards and reduced opportunities for exposure are associated with an increased risk of neurotropic infection (8).

In 1908, Landsteiner and Popper (9) demonstrated that the etiologic agent of poliomyelitis was a “filterable virus” in a series of experiments in which they induced paralysis and spinal cord lesions in a monkey by intraperitoneal injection of neural tissue from a fatal human case; shortly thereafter, Flexner and Lewis (10) at the Rockefeller Institute serially passed polioviruses in monkeys, fulfilling one of Robert Koch’s postulates.

Serologic surveys in the 1930s and 1940s helped define the basis for the observed differences in the behavior of epidemics in different locations and social conditions. Evidence of immunity was found in 80% to 100% of adults tested, with generally lower levels in children (11). In time, it was shown that the risk of infection was universal, but children living in poor sanitary conditions acquired infection at a much earlier age than children from higher socioeconomic backgrounds, an observation that explained the enigmatic shift during the early twentieth century from an endemic disease involving only young infants to an epidemic disease that also affected older children and young adults (12). Later studies conducted by Paul and Riordan (13) in a remote Eskimo population 15 to 20 years following outbreak of poliomyelitis showed that immunity persisted for at least two decades and perhaps for life.

The existence of more than one type of poliovirus was first inferred by Burnet and Macnamara (14) in 1931 when they demonstrated that monkeys who had recovered from infection with a strain recovered in Melbourne subsequently developed disease when given the virulent MV strain and showed that the two strains differed qualitatively in in vitro neutralization tests. These results were confirmed by Paul and Trask (11) at Yale and the two virus groups were respectively designated “Lansing”-like, or “Brunhilde”-like, the latter in reference to the name of a laboratory chimpanzee (1). A third type was predicted by the studies of Bodian (15), at Johns Hopkins in 1949. The existence of three types, and not more, was verified by the testing of poliovirus strains collected worldwide by a collaborative group organized by the National Foundation for Infantile Paralysis (16).

The era of effective poliomyelitis treatment began in the 1920s with the invention of the Drinker negative pressure ventilator or “iron lung” at the Harvard School of Public Health (17) and its development at several Boston hospitals (18). The earliest devices were powered by vacuum cleaners and were fitted with boat portholes for access to the body of the patient. Progress in the management of the persistently paralyzed patient was also made during this period. The practice of rigid immobilization of even mildly involved extremities for long periods gave way to the influential practices of Sister Elizabeth Kenny using warm, moist packs and prolonged physical therapy (19).

In 1936, Sabin and Olitsky (20) produced the first unequivocal evidence that polioviruses could be grown in vitro when they propagated the MV poliovirus strain in human embryonic central nervous system (CNS) tissue, and a decade later, Enders, Weller, and Robbins (21), succeeded in growing Lansing strain poliovirus in human embryonic tissues. This achievement is widely acknowledged as the landmark event that opened the door to further characterization of the virus, better understanding of the pathophysiology of poliomyelitis, and development of successful vaccines.

Building on these advances, Jonas Salk (22) developed the first successful inactivated poliovirus vaccine (IPV), which was first administered to paralyzed patients in a home for crippled children in Pittsburgh in 1952. In 1954 to 1955, Salk IPV was successfully tested in a monumental controlled trial involving more than 1.8 million U.S. schoolchildren. In the meantime, several investigators were studying live, attenuated polioviruses that could be delivered orally and induce mucosal as well as systemic immunity (23). Live attenuated poliovirus strains were tested in humans in several countries and ultimately, three monovalent strains developed by Sabin were licensed for use in the United States in 1961 and 1962. Over the next 2 years, more than 100 million oral poliovirus (OPV) vaccine doses were distributed in the United States via community programs organized by health departments and medical societies. Trivalent OPV vaccine was introduced in 1964 and remained the principal poliovirus vaccine used in the United States until 1997.

Figure 7.1 illustrates the reported incidence of paralytic poliomyelitis cases in the United States from 1920 to 1960. A peak of 55,000 cases was reported in 1952. The introduction of IPV vaccine for general use in 1955 and OPV vaccine in the early 1960s led to rapid and dramatic control of epidemic poliomyelitis, and the incidence of paralytic poliomyelitis fell from 13.9 cases per 100,000 in 1954 to less than 0.5 cases per 100,000 in 1965. By the 1970s, sustained transmission of naturally occurring polioviruses ceased and the last case of domestically acquired poliomyelitis was reported in 1979 (Fig. 7.2). Rare cases acquired in other countries continued to be imported into the United States in the 1980s, but control of poliomyelitis in the Western Hemisphere by 1991 resulted in virtual disappearance of imported cases. Approximately 8 to 10 vaccine-associated paralytic poliomyelitis (VAPP) cases following administration or transmission of OPV were observed until OPV vaccine was discontinued in favor of IPV in 1997 (24). Since then, only very rare poliomyelitis cases attributed to imported VAPP or to acquisition of OPV vaccine-derived polioviruses (VDPV) by immunodeficient persons have been reported in the United States (25,26).

000327

000330

VIROLOGY, TRANSMISSION, PATHOPHYSIOLOGY, AND IMMUNITY

Virology

The polioviruses are prototypical human enteroviruses (species: Enterovirus C; family Picornaviridae). Three poliovirus serotypes are distinguished from one another by in vitro neutralization with type-specific antisera. The icosahedral virion of approximately 27 nm in diameter is composed of a protein capsid and an enclosed single-stranded RNA genome of approximately 7,500 bases in length. The genome functions as a monocistronic message with a single open reading frame coding a 250 kDa polyprotein, which is subsequently cleaved by both viral coded and cellular proteases into capsid proteins, an RNA polymerase, proteases, and other regulatory proteins. The four capsid proteins (VP1 through VP4) combine to form the 60 structural subunits that are assembled into the viral capsid.

Like all picornaviruses, polioviruses exhibit substantial genomic variability with up to 15% variation within the capsid coding region for each serotype. The three Sabin OPV vaccine strains differ from their naturally occurring parents at fewer than 0.2% of positions across the full genome (27). For all three serotypes, analogous nucleotide substitutions in the 5′ noncoding region appear to be associated with diminished ability to replicate in the gastrointestinal tract and with diminished neurovirulence. Attenuating mutations also map to capsid proteins for each of the individual serotypes.

All three poliovirus serotypes share a common cell membrane receptor (poliovirus receptor [PVR]), a 67-kDa member of the immunoglobulin superfamily coded on human chromosome 19 (28,29). PVR-transgenic mice express PVR in CNS and muscle tissue, endowing susceptibility to these tissues but not on intestinal mucosal cells (30).

Transmission of Polioviruses

Before the introduction of poliovirus vaccines, naturally occurring polioviruses circulated in temperate climates with a marked seasonal variation resulting in peak activity from July to October and low levels from December to May. All three serotypes circulated concomitantly, although one or two types often predominated within a defined community during a single season. Horizontal transmission in the community occurred mostly among children 2 to 5 years of age, and data from virus watch studies indicated that poliovirus transmission was strongly associated with low socioeconomic status and household contact. Once virus was introduced into a household, 90% to 100% of susceptible persons became infected, along with 20% to 50% of seropositive persons (31). Adults were only slightly less likely to become infected than young children. After the introduction of OPV vaccine, the attenuated vaccine viruses replaced the epidemiologic niche inhabited by the naturally occurring viruses. The very low levels of person-to-person transmission of naturally occurring polioviruses during the winter and spring months probably abetted the disappearance of naturally occurring viruses and their replacement by OPV strains (32).

Pathophysiology

Ingested polioviruses implant in the oropharynx and small bowel and penetrate the mucosa via specialized microfold cells (M cells) and other epithelial cells overlying submucosal lymphoid tissues (33). In primate models, the most efficient site of viral replication is detected in Peyer patches in the intestinal submucosa (34,35). Spread to regional lymph nodes gives rise to a transient and clinically silent “minor” viremia during which virus spreads to systemic reticuloendothelial tissue including lymph nodes, bone marrow, liver, and spleen (36). For most poliovirus infections, viral replication is contained at this stage, resulting in subclinical infection. In a minority of infections, further replication of virus in reticuloendothelial tissues leads to a “major” viremia, which coincides with the onset of fever and other clinical symptoms (37).

The path by which polioviruses reach the CNS remains unsettled. It is well established that viremia precedes paralysis, but the precise mechanism by which the virus breaches the blood–brain barrier is not known (38,39). A study using transgenic mice bearing the PVR gene found that spinal cord involvement can be blocked by sciatic nerve section after virus is injected intramuscularly (40), suggesting that virus replication in skeletal muscle precedes transport of virus to the cord via the peripheral nerve (41,42), a concept consistent with the myotropic nature of enteroviruses and the clinical observation of intense myalgias preceding the onset of paralysis in affected patients.

Polioviruses are recoverable from the spinal cord for only the first several days of paralysis. The necrotic lesions and inflammatory infiltrates (Fig. 7.3C), which are distributed within the gray matter of the anterior horn of the spinal cord, the motor nuclei of the pons and medulla, and occasionally other locations (Fig. 7.3A and B), may persist for months (43). The severity of clinical paralysis depends more on the intensity of the lesions, rather than their distribution.

00334

Immunity

Immunity to poliovirus infection is type specific; cross protection between the three serotypes is low, if it exists at all. Reinfection with the same serotype occurs upon exposure to live poliovirus, regardless of whether prior immunity is based on infection with naturally occurring polioviruses, infection with live, attenuated viruses, or inactivated poliovirus vaccine administration. After household exposure to wild type virus, 20% to 50% of naturally immune (31), 30% to 50% of OPV immune, and 90% to 100% of IPV immune persons are reinfected, as defined by virus excretion from the gastrointestinal tract or rise in antibody titer. Reinfections are universally asymptomatic and are rarely associated with oropharyngeal virus excretion.

Passively acquired poliovirus antibody protects against disease, but not against infection (44). Preexisting humoral antibody prevents or reduces oropharyngeal shedding of poliovirus upon reinfection but has only a minor effect on fecal shedding (38,4547). Serum-neutralizing antibodies are made in response to natural infection and to immunization with either OPV or IPV vaccine. Antibodies made in response to natural infection appear to persist for life (48), and it is presumed that vaccine-induced protection is long term, if not lifelong.

Poliovirus secretory immunoglobulin A (IgA) appears in nasopharyngeal and intestinal secretions 1 to 3 weeks after natural infection or administration of OPV vaccine (49). Secretory IgA antibody persists for at least 5 to 6 years at low levels and, unlike humoral antibody, is not boosted significantly upon rechallenge with OPV vaccine (50). The degree of protection conferred by local IgA antibody is relative. Upon rechallenge, high secretory IgA titers inhibit virus replication, whereas lower titers permit replication; virus shedding is dependent on the challenge dose (46,51). Studies in the field show that childhood recipients of OPV are often reinfected and shed OPV virus in feces despite multiple prior OPV doses (52,53).

CLINICAL FEATURES OF POLIOMYELITIS

Acute Illness

More than 90% of naturally occurring poliovirus infections are inapparent. Acute clinical poliomyelitis is traditionally separated into two distinct phases: the “minor illness” with an incubation period of 3 to 7 days and the “major illness” with onset of symptoms generally 9 to 12 days after exposure (54). The minor illness, coinciding with viremia, consists of nonspecific symptoms such as fever, headache, sore throat, anorexia, and listlessness. Overall, 4% to 8% of infected persons experience symptoms of the minor illness, and most resolve their illness within 1 to 2 days without further symptoms.

The major illness is associated with CNS infection, which has been variously estimated to occur in 0.1% to 1.0% of all poliovirus infections (8,55). About one third of young children who develop the major illness experience a biphasic illness with symptoms of the minor illness preceding onset of CNS disease; adults usually develop CNS disease without the preceding minor illness (37,56). The major illness is heralded by the abrupt onset of fever, headache, vomiting, and meningismus (Table 7.1). CSF pleocytosis is present at this early stage. Approximately one third of cases of CNS disease are limited to meningitis without detectable motor neuron impairment, which resolves within 5 to 10 days (i.e., “nonparalytic poliomyelitis”).

000338

Muscle weakness is preceded by intense myalgias of the involved limb(s) and the axial skeleton. The pain may be relieved by exercise; patients may pace nervously in an attempt to “work off” the pain. The hallmark of poliomyelitis is asymmetric motor paresis, which ranges from mild weakness of a single extremity to complete quadriplegia. Proximal limb muscles are more involved than distal, and legs are more commonly involved than arms. The deep tendon reflexes, which were initially brisk, become absent. The pace of development of the paresis ranges from several hours to several days; most commonly occurring over 2 to 3 days. Cranial nerve involvement (i.e., “bulbar poliomyelitis”) occurs in 5% to 35% of paralytic cases. Any of the motor cranial nerves can be involved, with the ninth and tenth being the most common.

Complications

Bulbar paralysis results in dysphagia, nasal speech, dyspnea, difficulty managing secretions, anxiety, and respiratory compromise. Involvement of respiratory and vasomotor nuclei is less common but may portend serious complications due to hypoventilation, blood pressure lability, and cardiac arrhythmias. Respiratory failure from paralysis of the diaphragm and intercostal muscles represents the most serious complication of paralytic poliomyelitis. Aspiration pneumonia, pulmonary edema, myocarditis, paralytic ileus, gastric dilation, and ileus of the bladder may also complicate acute paralytic disease.

Prognosis

Paralysis most often progresses for 1 to 3 days after onset, rarely more than a week, halting about the time the patient becomes afebrile (57). Most patients with limb paresis experience some recovery of function in the weeks to months after acute disease. An estimate of the eventual outcome can be made by a month after onset when most reversible weakness will have resolved. Very little additional recovery of strength can be expected after a period of 9 months. Residual motor deficits remain in about two thirds of initially paralyzed patients, ranging from minor debility to permanent, flaccid paralysis.

Overall mortality for spinal poliomyelitis is about 4% to 6%. During the poliomyelitis epidemics in the 1940s and 1950s, bulbar polio caused a mortality of 20% to 60% when respiratory assistance was required. With modern intensive care, deaths from temporary respiratory paralysis should be less common.

Differential Diagnosis

Sporadic cases of paralytic disease due to the nonpolio enteroviruses and West Nile virus is clinically indistinguishable from poliomyelitis. Only two nonpolio serotypes have been known to cause epidemic disease: coxsackievirus A7 virus, which has caused small outbreaks of paralytic disease in the former Soviet Union (58), South Africa, and Scotland (59), and enterovirus 71, which has caused large outbreaks in Eastern Europe in the late 1970s and more recently in several countries in Southeast Asia (6062).

Poliomyelitis must also be distinguished from other causes of acute paralysis including the Guillain-Barré syndrome, which is associated with paralysis that is classically ascending in nature, symmetric, and is accompanied by sensory abnormalities in approximately 80% of cases. The CSF pleocytosis that occurs during the major illness of poliomyelitis is not characteristic of the Guillain-Barré syndrome, which is associated with a normal CSF leukocyte count and an elevated CSF protein concentration. Other conditions produce acute paralysis, including transverse myelitis, botulism, tick paralysis, epidural abscess, cord tumors, and hysteria; however, each of these diseases has features that readily separate them from acute poliomyelitis.

Risk Factors

Although it was once believed that adults are more susceptible to paralytic complications, there is probably little correlation of age with severity of disease after the decline of maternal antibody (8,55). Studies during outbreaks suggest that infected pregnant women have an increased risk of developing paralytic disease (63,64). There is no evidence that either naturally occurring polioviruses (65) or attenuated vaccine polioviruses (66) cause congenital defects.

Persons with B-cell immunodeficiency, primarily young children with X-linked immunodeficiency syndromes, have an increased risk of CNS disease when infected with either naturally occurring or attenuated vaccine polioviruses. These patients may develop acute paralysis or may have an atypical course with an incubation period of several months, prolonged febrile illness, chronic meningitis, and progressive neurologic dysfunction that includes both upper and lower motor neuron involvement (6770).

Strenuous exercise during the early stages of the major illness substantially increases the risk and severity of poliomyelitis. This effect has been well documented clinically (71,72); and experimental infections with other enteroviruses provide supportive evidence (73).

Paralytic poliomyelitis tends to localize in a limb that has been the site of a recent intramuscular injection or injury (7476). Observations in experimental poliomyelitis (39,40) and after the administration of OPV vaccine (77) confirm this association but do not fully explain the mechanism of the provoking effect. Tonsillectomy during the incubation period of poliomyelitis markedly increases the risk of bulbar disease (78). The mechanism may be similar to the provoking effect of injections on spinal poliomyelitis.

POSTPOLIOMYELITIS SYNDROME

As many as 20% to 30% of patients who recover from paralytic poliomyelitis experience new onset of muscle weakness, pain, atrophy, and fatigue many years after the acute illness. With the eradication of acute poliomyelitis, the postpolio syndrome remains the sole polio-related clinical disease encountered by physicians in all but a few polio-endemic nations. It is expected that the postpolio syndrome will ultimately decline in incidence and disappear as poliomyelitis is controlled around the globe.

History and Background of the Postpoliomyelitis Syndrome

In 1875, Charcot (79) described a relationship between acute poliomyelitis and late development of motor neuron degeneration. By 1969, approximately 83 cases had been described in which motor neuron degeneration occurred decades after acute poliomyelitis (80), although the distinction between what we now describe as postpolio syndrome and other possible causes of late denervation, such as amyotrophic lateral sclerosis (ALS), was not possible in many of these cases. The hypothesis was advanced that the incidence of late motor neuron disease might increase as children affected during the epidemics of the 1950s reached middle age (81,82). Initial concern that paralytic poliomyelitis might increase the risk of subsequent ALS was allayed by careful epidemiologic studies, suggesting that prior infection with poliomyelitis might actually protect against the subsequent development of ALS (83). At present, it seems clear that the etiology and natural history of the postpolio syndrome and ALS are quite different. Postpolio syndrome is an indolent condition that rarely leads to severe disability or death (84).

Nomenclature

Although the term postpolio syndrome has sometimes been applied to all neurologic symptoms occurring as late manifestations of poliomyelitis, most authorities reserve this designation for a disorder characterized by new-onset muscle weakness, fatigue, and pain, associated with loss of function that occurs years after the original acute poliomyelitis episode (8587). Another term, postpolio progressive muscular atrophy (PPMA) refers specifically to the weakness with or without atrophy that results from late denervation of muscles of patients (8891). Criteria for PPMA include a reasonable past history of poliomyelitis with partial recovery of function and at least a decade of stabilization after recovery from the initial illness. PPMA is then the development of progressive muscular weakness following these antecedent criteria. It is worth noting that atrophy probably occurs in only half or fewer of the patients who develop new weakness (92). Although the terms postpolio syndrome and PPMA are used almost interchangeably, it should be recognized that postpolio syndrome or postpoliomyelitis sequelae may include other symptoms such as fatigue (undoubtedly the most common of all symptoms), subjective alterations in attention or cognition, sleep disturbance, and alterations in pain perception. Bulbar symptoms, including dysphagia and some pulmonary disturbances, can occur and may be more common and severe in those who had bulbar symptoms during their childhood illness.

Epidemiology and Risk Factors

Epidemiologic studies indicate that postpolio syndrome affects a substantial proportion of the 250,000 to 640,000 polio survivors estimated to live in the United States (83,86,93). A cohort study of 300 persons living in Olmsted County, Minnesota, who had contracted paralytic poliomyelitis between 1935 and 1955 found that 32 (64%) of 50 poliomyelitis survivors had symptoms consistent with postpolio syndrome, and in another retrospective study of Allegheny County, Pennsylvania, residents with a history of paralytic poliomyelitis noted a prevalence of 28% (94,95). In the latter study, female gender and permanent impairment sustained at the time of acute polio infection seemed to convey a higher risk of developing postpolio syndrome. However, the strongest risk factor for developing postpolio syndrome was the interval from the original paralytic disease with the incidence of postpolio syndrome peaking 30 to 34 years after the original illness. Older age at the time of presentation with postpolio syndrome has also been identified as a risk factor (86).

Etiology

Although the precise cause of postpolio syndrome remains unknown, there is a consensus among authors that the cause is probably related to exhaustion of motor units previously overstressed by recovery from the acute denervation during acute polio virus infection following which terminal elements of surviving alpha motor neurons sprout to reinnervate adjacent myofibrils. After acute poliomyelitis, fewer anterior horn cells innervate a relatively larger number of myofibrils, thereby exaggerating the effects of the additional, physiologic cell loss at a later date attributed to aging (92,96).

Other possible mechanisms have been considered, including immunologic events and other virus–host interactions. Prime among these alternative theories is the conjecture that polioviruses can persist for many years within the CNS of patients with postpolio syndrome and cause recrudescent disease by direct viral infection or immunopathologic pathways (97). Evidence in support of this theory includes the demonstration of oligoclonal immunoglobulin G bands (84,98) or poliovirus-specific immunoglobulin M bands (99) in CSF, and the demonstration of poliovirus-like RNA sequences in CSF of postpolio syndrome patients by the polymerase chain reaction (100). However, the presence of CSF oligoclonal bands has been inconsistent across studies (101,102), and virologists debate the likelihood of infectious virus, or even viral RNA, persisting for long periods in immunocompetent hosts.

Pathophysiology

Physical fatigue may result from damage to motor units in previously affected muscle (103106), perhaps associated with a change in acetylcholine receptor sensitivity and/or number. (This has a practical ramification for anesthesiologists who may find it prudent to reduce the dose of paralytic agents for patients with postpolio syndrome [107].) During exercise, there is decreased maximal voluntary contraction of muscles affected by postpolio syndrome, decreased tetanic force, and delayed recovery. Based on these and other data, Sharma et al. (106) hypothesize that muscle fatigue in postpolio syndrome may be due to impaired activation beyond the muscle membrane at the level of excitation–contraction coupling. Based on neuropathologic studies of patients with poliomyelitis in the 1940s and 1950s, another hypothesis suggests that the fatigue experienced by patients with postpolio syndrome has a central origin. These studies showed lesions in specific areas of the brain whether or not clinical symptoms of encephalitis had occurred, including the reticular formation in the brainstem, vestibular nuclei, cerebellar nuclei, periaqueductal gray, hypothalamic and thalamic nuclei, substantia nigra, locus ceruleus, and median raphe nuclei (43,107,108). The reticular activating system, responsible for maintaining normal alertness and attention, is composed of the brainstem reticular formation, posterior hypothalamus, and thalamus. Specific injuries to these structures from poliovirus infection could cause the acute disorientation and depression of consciousness seen in acute poliomyelitis and hypothetically could set the stage for late-onset decompensation of arousal, attention, and subjective cognition in postpolio syndrome (109,110). It has been suggested that T2-weighted hyperintense areas observed on brain magnetic resonance imaging (MRI) scans could represent these areas of polio virus–induced damage (111) (Fig. 7.4). Injury to the periaqueductal gray of the brainstem and substantia gelatinosa of the posterior horn of the spinal cord may explain the hyperpathia that is reported by many polio survivors (111).

000343

Clinical Features

Fatigue, which may be the most distressing and disabling symptom, is also the most common complaint, occurring in 91% of polio survivors in national surveys (89,96,103,112). Of these individuals, 41% experienced work limitation and 25% had interference with self-care (111). Patients also report mental fatigue affecting attention and concentration (103).

The most common neurologic sign of postpolio syndrome is new weakness, which may be accompanied by atrophy and pain. Weakness occurs in those muscles previously weakened during acute paralytic poliomyelitis or in muscles thought to be previously unaffected and may increase with exertion. The pain may be perceived in muscles or joints and can occur in the presence or absence of weakness. Joint pain may occur because chronic residual weakness leads to abnormal joint stresses. Scoliosis, poor mechanics, and abnormal postures may all contribute. The degree of actual osteophytic change may be less than one might anticipate given the amount of residual weakness. Muscle pain may result from chronic denervation or, if residual weakness is present, merely from overuse of muscles. Secondary myopathy with elevation of creatine kinase levels, usually of a mild degree, may occur in some patients (95).

Postpoliomyelitis dysphagia, whether simply residual or progressive could be a consequence of bulbar motor nerve injury. Attention to the problems of dysphagia in patients with postpolio syndrome was first drawn by Sonies and Dalakas (113), who suggested that it was analogous to the postpolio syndrome seen in the limbs, based on their series in which all but 1 of the 32 patients studied had some abnormality in swallowing function. Cinefluorography can demonstrate whether there are impaired movements of the tongue, aspiration, or pooling of material in the pyriform sinuses or valleculae. Aspiration seems to be found only very infrequently and probably does not pose a severe risk in most instances (93,113). Other symptoms that might be attributed to late-onset bulbar dysfunction include the sleep-disordered breathing and chronic alveolar hypoventilation that sometimes develop in patients with postpolio syndrome (114). Sleep-disordered breathing may include obstructive sleep apnea syndrome and may occur more commonly in patients with postpolio syndrome who suffered insult to respiratory control centers in the brainstem at the time of their primary infection. Pulmonary function may be further compromised if weakness of respiratory muscles, impaired swallowing or cough mechanisms, chest wall deformity, or poor thoracoabdominal interaction is present (115).

Electrophysiology

Conventional electromyography (EMG) demonstrates chronic denervation and occasionally reveals new or ongoing denervation in the form of fasciculations, fibrillations, and positive sharp waves (87,91,116). Both symptomatic and asymptomatic patients with postpolio syndrome show similar EMG findings. Similarly, the chronic denervation and reinnervation signs (including both enlarged and polyphasic motor unit potentials) and decreased interference patterns are seen whether or not the muscle being tested was originally weak (91,92,117). Enlarged motor units consistent with highly increased fiber density can be demonstrated in 90% of patients with postpolio syndrome with single-fiber EMG (90). Jitter and neuromuscular blocking effects are also noted, which correlate with the interval since acute poliomyelitis. Like conventional EMG, single-fiber EMG is unable to distinguish symptomatic and asymptomatic patients with postpoliomyelitis. In contrast, macro-EMG may distinguish muscles with new weakness, because previously increased amplitudes decline with new weakness and atrophy (90).

Although electrophysiologic studies in postpolio syndrome and PPMA have provided important pathophysiologic information and supported the etiologic concept of overuse or accelerated aging of overcompensated motor units, the primary clinical role for nerve conduction and EMG studies is to exclude other causes for the patient’s complaints.

Psychologic Issues

Although the cardinal manifestations of postpolio syndrome are neither caused nor modified by psychopathologic or personality factors, patients with postpolio syndrome may be subject to characteristic psychologic symptoms (110,116,118). Bruno et al. (112) argue that anxiety, depression, and compulsive behavior occur frequently in polio survivors, resulting from the experience of a disabling disease in childhood from which recovery was achieved only by extreme effort (118). Success in obtaining independence and in overcoming a disability was often accomplished by adopting very compulsive behavior and demanding very high standards of themselves. One of the goals that many individuals set was to overcome the need for assistive devices such as braces, crutches, wheelchairs, and the like. In consequence, polio survivors achieved higher than expected life goals.

Effects of Exercise

Unfortunately, the avoidance of assistive devices at the time of acute weakness may be maladaptive in subsequently dealing with postpolio syndrome (112). Overtaxing motor units with exercise may contribute to irreversible damage to muscle fibers and more severe weakness (88,119,120). Patients with postpolio syndrome may benefit from rest periods, increased sleep time, and other energy-conservation methods to overcome fatigue (121). Compliance with appropriate intervention to correct the overuse pattern appears to result in improvement or resolution of new weakness and fatigue (122). However, because disuse can also enhance weakness, some moderation must be sought. Muscle strength may be improved by nonfatiguing exercise (123). Specific protocols for high-resistance exercise to improve isokinetic and isometric strength for patients with postpolio syndrome have been described (124,125).

POLIOVIRUS VACCINES

Inactivated Poliovirus Vaccine

IPV vaccine is prepared by inactivation of poliovirus seed strains by formalin treatment for 12 to 14 days at 37°C, the method originally developed by Jonas Salk. However, contemporary IPV vaccines contain higher concentrations of all three antigens compared with IPV vaccines introduced in the 1950s. Three IPV formulations are now distributed in the United States: trivalent IPV (IPOL, Aventis Pasteur) and trivalent IPV combined with other recommended childhood vaccines (Pediatrix, GlaxoSmithKline and Pentacel, Sanofi Pasteur). Most available IPV vaccines are produced from wild type polioviruses grown in monkey kidney cells and contain 40-, 8-, and 32-D antigen units, respectively, for poliovirus serotypes 1, 2, and 3. IPV formulations produced from Sabin OPV vaccine strains are under development in China and elsewhere. The primary vaccination series for IPV vaccine in the United States consists of four doses administered at 2 months, 4 months, 6 to 18 months, and 4 to 6 years of age (126). Since 2000, IPV vaccine has been used exclusively in the United States for routine immunization of infants against poliomyelitis and for all other recipients including unimmunized adults, immunodeficient persons, and anyone requiring polio vaccine boosters to travel to poliovirus endemic regions (126).

Neutralizing antibodies are detectable to all three poliovirus types in 99% of IPV vaccine recipients after two doses and 100% after the third dose (127,128). A large boost in antibody titer follows the third dose (127,128). After three doses, mean titers to types 1 and 3 are higher than in OPV-immunized children, whereas mean titers to type 2 are equivalent. Detectable antibody persists at protective levels for at least 5 years, although mean titers decline considerably (128). Vaccine efficacy for IPV distributed in the 1960s was estimated to be 91% and 95% for 3 and 4 doses, respectively. There are few data regarding vaccine efficacy of the current IPV formulations. A case–control study in Senegal indicated protection rates of 36% and 89% for recipients of one and two doses, respectively (129). The efficacy for three doses is assumed to be higher.

IPV-immunized children develop little or no measurable secretory antibody (49). When challenged with live polioviruses, IPV-immunized children shed the challenge virus in their feces at a higher rate, higher titer, and for a longer period than OPV-immunized children (51), indicating a greater potential for asymptomatic infection and transmission of circulating polioviruses to unimmunized contacts. Although this is widely considered to be a disadvantage of IPV, there is strong evidence that widespread use of IPV results in protection that extends to unvaccinated persons in the community in developed nations with good sanitation (130,131). IPV vaccine may reduce community transmission of polioviruses due to reduction of pharyngeal shedding of poliovirus in reinfected IPV vaccine recipients, which may be the important mode of community spread (47), although there is little effect of IPV vaccine in preventing spread within families in which fecal-oral spread may be a more important mode of transmission (132,133).

Live, Attenuated Poliovirus Vaccine

Live, attenuated trivalent (tOPV) vaccine remains the principal vaccine used throughout the developing world. There are different manufacturers worldwide, but most follow a common production method in which Sabin seed strains representing each of the three poliovirus serotypes are individually grown in monkey kidney cells and are combined for oral administration in concentrations of approximately 106.0TCID50, 105.1 TCID50, and 105.8 TCID50 for poliovirus types 1, 2, and 3, respectively. The unequal contribution of each type to the trivalent preparation represents a “balanced” formulation designed to account for the more efficient replication of type 2 OPV vaccine in the gastrointestinal tract (134). Because type 2 virus regularly interferes with replication of types 1 and 3, a primary series of three doses are routinely administered to enhance seroconversion to all three serotypes. Under conditions of good hygiene, seroconversion rates of 50%, 85%, and 30% to serotypes 1, 2, and 3, respectively, are achieved following the first tOPV dose (135), and a second and third tOPV dose induce neutralizing antibodies to all three types in 86% and 96%, respectively (127,136). Serum antibody to all three types persists in 84% to 98% of vaccinees 5 years after primary immunization (137), although reexposure to vaccine viruses probably aids the maintenance of antibody levels in the population. Secretory IgA poliovirus antibody appears in oropharyngeal and duodenal secretions 1 to 3 weeks after OPV immunization (49) and persists for at least 5 to 6 years (138). Challenge studies suggest that the intestinal immunity induced by OPV vaccine is similar to intestinal immunity following natural infection (139).

The WHO Expanded Program on Immunization (EPI) recommends one dose of tOPV at birth, a practice that provides an opportunity to administer at least one dose of vaccine to a child who may not present for routine health maintenance care later, and three tOPV doses at 6, 10, and 14 weeks of age (140). Even though passively acquired maternal antibody to polioviruses present in the infant’s circulation and in breast milk reduces vaccine virus replication in the gastrointestinal tract and therefore blunts the immune response in some infants, infants who receive OPV at birth are more likely to have antibody to all three poliovirus types at 4 months of age (141). Seroconversion rates to tOPV are lower in many tropical countries compared to seroconversion rates in developed countries (142144). Poor responses to tOPV have contributed to outbreaks of poliomyelitis in Oman, Israel, and Brazil despite relatively high immunization rates existing before the appearance of epidemic disease (145147). Although the reasons for the lower potency of tOPV vaccine in tropical areas remain incompletely understood, concurrent diarrheal disease at the time of immunization is an important factor (148,149).

Monovalent type 1 (mOPV1), monovalent type 3 (mOPV3), and bivalent type 1 and type 3 (bOPV) were added to the Global Polio Eradication Program in 2006 and 2009, respectively to enhance seroconversion rates to type 1 and type 3 OPV in the absence of the type 2 vaccine virus (150). Studies in Egypt and South Africa have confirmed the superior immunogenicity of the monovalent vaccines compared to tOPV in resource poor settings (151,152).

Nonimmune OPV recipients shed vaccine viruses in the feces for 1 to 6 weeks and from the oropharynx for 1 to 3 weeks. The spread of OPV viruses to unimmunized children is an advantage in areas in which immunization levels are low. For example, a seroprevalence study in Houston and Detroit found that 11% to 42% of 11- to 35-month-old children possessed poliovirus neutralization antibodies, despite receiving no prior OPV vaccine (153).

Vaccine-Associated Paralytic Poliomyelitis

The only serious adverse reaction associated with OPV is the rare occurrence of VAPP. The incidence of VAPP has been estimated to be 2 to 4 cases per million individuals per year in countries using OPV (154). In industrialized countries, the relative frequency of paralysis associated with the first dose in the OPV series is about 10-fold higher than with subsequent doses, whereas in developing countries, this ratio is lower, probably due to lower vaccine effectiveness (155). OPV virus types 3 and 2 were most common causes of VAPP in the United States prior to discontinuation of OPV use in 2000 (155). Approximately half of VAPP cases are recent OPV vaccinees, most of whom develop paralysis 7 to 21 days after the first feeding of OPV. A similar number of cases occur among parents, other family members, or other household contacts that develop paralysis several weeks after the administration of OPV to a close contact.

Persons who have transient or hereditary B-cell immunodeficiency, severe combined immunodeficiency syndrome, or common variable immunodeficiency have an elevated risk of VAPP (69,156). For immunodeficient VAPP patients, interval between the last OPV dose and onset of neurologic disease is unusually long, with a typical range of 1 to 8 months, and has been documented to be as long as 7 years (70). The illness may be protracted with chronic meningitis, progressive neurologic dysfunction suggesting involvement of both upper and lower motor neurons, progression of paralysis over several weeks, and high mortality (67,68). Although fewer than 20% of surviving VAPP patients excrete polioviruses for longer than 6 months (70), fecal excretion of virus has been estimated to occur for as long as 18 years in one immunodeficient patient (157).

GLOBAL CONTROL OF POLIOMYELITIS

With some notable exceptions (158), paralytic poliomyelitis affects mostly children between the ages of 6 months and 2 years in developing countries, and most cases are caused by type 1 poliovirus. Lameness surveys of school-aged children in more than 20 developing nations revealed lower limb paralysis prevalence rates of 2 to 11 per 1,000 in the 1960s and 1970s, prevalence rates that equal or exceed those of the peak epidemic years in the United States (159,160). Currently, OPV vaccine is used almost exclusively in underdeveloped nations because of lower cost, ease of administration, enhanced mucosal immunity, and enhancement of population immunity through transmission of vaccine viruses from immunized children to nonimmune contacts.

Following the successful eradication of smallpox, an international conference held in Bellagio, Italy in 1983 articulated the possibility of poliomyelitis eradication based on the unique epidemiology of poliovirus infections and the widespread availability of an inexpensive oral vaccine (tOPV) (161,162). By 1991, the Pan American Health Organization succeeded in eradicating polio in the Americas, and in 1988, the World Health Assembly resolved to eradicate polio globally by the year 2000 (163165). The Global Poliomyelitis Eradication Initiative (GPEI) is a consortium of international partners led by the WHO (159,166). The principal strategies employed by the GPEI include enhancement of routine infant tOPV immunization, the conduct of large scale supplementary immunization activities (SIAs) targeting all children younger than 5 years of age, surveillance for poliomyelitis cases through identification of persons with acute flaccid paralysis (AFP), and maintenance of a global network of laboratories capable of identification and characterization of polioviruses in fecal specimens obtained from AFP cases. Seroconversion rates during SIAs are higher than for routine immunization (167), possibly because of spread of OPV or because they are conducted during the dry season when diarrheal disease is less prevalent. In the Americas, twice yearly mass campaigns were credited with rapid cessation of poliovirus circulation and disappearance of disease (168,169).

Although there has been a reduction of more than 99% in the burden of paralytic poliomyelitis and circulation of type 2 polioviruses ceased in 1999, the goal of complete eradication has proven to be more difficult to attain than originally anticipated (170172). Progress stalled in the last decade due to inability to stop transmission in some highly endemic areas, exportation from these areas to previously polio-free nations, social and cultural opposition to OPV immunization, civil unrest, funding gaps, and the emergence of VDPV in areas with low OPV coverage (173,174). Eventually, many of the social, cultural, and political barriers were addressed, and in the mid-2000s, the deployment of monovalent and bivalent OPVs during SIAs led to improved seroconversion rates in many countries affected by low tOPV potency. These new formulations are now credited with the eventual elimination of poliomyelitis in India and the marked reduction in case load in some particularly challenging areas in sub-Saharan Africa (166).

Vaccine-Derived Polioviruses

One unanticipated challenge to global poliomyelitis eradication is the emergence of virulent polioviruses derived from OPV vaccine strains among underimmunized children living in certain economically deprived regions (175,176). A retrospective laboratory investigation demonstrated previously unrecognized type 2 VDPV isolates that circulated in Egypt from approximately 1982 to 1993, and global surveillance since 2000 has uncovered more than 15 subsequent VDPV outbreaks representing all three poliovirus serotypes (177). All VDPV strains have been isolated from regions with low OPV coverage, permitting VDPV to circulate, and all have acquired biologic properties that are indistinguishable from naturally occurring wild type polioviruses, including neurovirulence in monkeys and transgenic mice (178,179).

The discovery of the potential for reintroduction of virulent polioviruses into previously polio-free areas via generation of VDPV has reinforced the necessity of maintaining high immunization levels in all polio-free regions and has created the necessity of discontinuing the use of all live, attenuated poliovirus vaccines once eradication of naturally occurring poliovirus disease is assured (180,181).

OUTLOOK

As of 2013, renewed commitment to eradication has reduced the number of polio-endemic nations to three—Nigeria, Afghanistan, and Pakistan—and the annual global case count to less than 300, and there is hope that the mission to eradicate will soon be met. The polio “endgame” now calls for replacement of tOPV by bOPV once the threat from type 2 circulating vaccine-derived poliovirus (cVDPV) is diminished and the ultimate discontinuation of all live OPV and a phased introduction of IPV. IPV is known to be highly immunogenic when administered to infants and children in resource-poor settings (182185) and has shown promise as a supplement to OPV in similar settings (147,186188). Furthermore, strategies are being developed to overcome the higher costs associated with IPV production, delivery, and storage, including development of dose reduction by intradermal injection, development of new adjuvants, and combination of IPV with other vaccines routinely administered to infants (174).

SUMMARY

Epidemic paralytic poliomyelitis is a disease that has both appeared and disappeared during the past 120 years. Most medical practitioners in industrialized countries have never seen a case of acute poliomyelitis but may encounter patients who are now developing the symptoms of postpolio syndrome. The clinical, epidemiologic, and scientific foundations for the control of poliomyelitis were laid in the first half of the twentieth century. Now, eradication has been achieved throughout the developed world by routine immunization programs using two very effective vaccines, each of which possesses unique advantages and disadvantages. In recent years, IPV has become the preferred vaccine for developed countries because of the risk of rare VAPP cases associated with OPV.

Attention is now focused on the few remaining locations where polio remains endemic. Despite setbacks, new strategies are being deployed and real progress has been made in recent years. Hopefully, the goal of global poliomyelitis eradication will be achieved before the next edition of this text is published. The posteradication phase will require continued surveillance, maintenance of vaccine stockpiles for use should virulent polioviruses reemerge, and containment of laboratory stocks of naturally occurring and attenuated polioviruses (189). The discovery of VDPV in multiple locations has limited the options available for eventual discontinuation of polio immunization and underscored the critical need to maintain active surveillance and high levels of immunity worldwide for many years (180,181).

References

1. Paul JR. History of Poliomyelitis. New Haven Yale University Press; 1971.

2. Lockhart JG. Memoirs of the Life of Sir Walter Scott, Bart. Philadelphia: Carey Lean and Blanchard; 1837.

3. Underwood M. A Treatise on the Diseases of Children, with General Directions for the Management of Infants from the Birth. 2nd ed. London: Mathews; 1789.

4. Heine J. Beobachtungen über Lähmungszustände der unteren Extremitäten und deren Behandlung. Stuttgart: Köhler; 1840.

5. Charcot JM. Groupe des myopathies de cause spinale: paralysie infantile. Rev Phot Hop (Paris). 1872;4:1–36.

6. Vermont State Department of Public Health. Infantile Paralysis in Vermont. Brattleboro: Vermont Printing Co; 1924.

7. Wickman I. Beiträge zur Kenntnis der Heine-Medinschen Krankheit (Poliomyelitis Acuta und Verwandter Erkrankungen). Berlin: Karger; 1907.

8. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance and disappearance. Am J Epidemiol. 1979;110:672–692.

9. Landsteiner K, Popper E. Mikroscopische präparate von einem menschlichen und zwei affenrückemarken. Wien Klin Wochenschr. 1908;21: 1830.

10. Flexner S, Lewis PA. The transmission of poliomyelitis to monkeys. JAMA. 1909;53:1639.

11. Paul JR, Trask JD. The neutralization test in poliomyelitis: comparative results with four strains of the virus. J Exp Med. 1935;61:447–464.

12. Turner TB, Young LE, Maxwell ES. Mouse-adapted Lansing strain of poliomyelitis virus: neutralizing antibodies in serum of healthy children. Am J Hyg. 1945;42:119–127.

13. Paul JR, Riordan JT. Observations on serological epidemiology. Am J Hyg. 1950;52:202–212.

14. Burnet FM, Macnamara J. Immunological differences between strains of poliomyelitic virus. Br J Exp Pathol. 1931;12:57–61.

15. Bodian D. Second attacks of paralytic poliomyelitis in human beings in relation to immunity, virus types and virulence. Am J Hyg. 1951;54:174–190.

16. Committee on Typing of the National Foundation for Infantile Paralysis. A cooperative program for the typing of one hundred strains. Am J Hyg. 1951;54:191–274.

17. Drinker P, McKhann CF. The use of a new apparatus for the prolonged administration of artificial respiration: a fatal case of poliomyelitis. JAMA. 1929;92:1658.

18. Drinker P, Shaw LA. Apparatus for prolonged administration of artificial respiration: design for adults and children. J Clin Invest. 1929;7:229.

19. Pohl JF, Kenny E. The Kenny Concept of Infantile Paralysis and Its Treatment. Minneapolis: Bruce; 1943.

20. Sabin AB, Olitsky PK. Cultivation of poliovirus in vitro in human embryonic nervous tissue. Proc Soc Exp Biol Med. 1936;34:357–359.

21. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science. 1949;109:85–87.

22. Salk JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. JAMA. 1953;151:1081–1098.

23. Sabin AB. Oral polio vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985;151:420–436.

24. Nkowane BM, Wassilak SCF, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;257:1335–1340.

25. DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med. 2011;364(24): 2316–2323.

26. Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis. 2009;199(3):391–397.

27. Almond JW. The attenuation of poliovirus neurovirulence. Ann Rev Microbiol. 1987;41:154–180.

28. Mendelsohn CL, Johnson B, Lionetti KA, et al. Transformation of a human poliovirus receptor gene into mouse cells. Proc Natl Acad Sci U S A. 1986; 83:7845–7849.

29. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin super family. Cell. 1989;56:855–865.

30. Ren R, Costantini F, Gorgacz EJ, et al. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 1990;63: 353–362.

31. Gelfand HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg. 1957;65:367–385.

32. Yorke JA, Nathanson N, Pianigiani G, et al. Seasonality and the requirements for perpetration and eradication of viruses in populations. Am J Epidemiol. 1979;109:103–123.

33. Iwasaki A, Welker R, Mueller S, et al. Immunofluorescence analysis of poliovirus receptor expression in Peyer’s patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J Infect Dis. 2002;186:585–592.

34. Bodian D. Emerging concept of poliomyelitis infection. Science. 1955; 122:105–108.

35. Sabin AB. Behavior of chimpanzee-avirulent poliomyelitis viruses in experimentally infected human volunteers. Am J Med Sci. 1955;230:1–8.

36. Bodian D. Poliovirus in chimpanzee tissues after virus feeding. Am J Hyg. 1956;64:187.

37. Horstmann DM. Clinical aspects of acute poliomyelitis. Am J Med. 1949;6:592.

38. Bodian D. Viremia in experimental poliomyelitis. I. General aspects of infection after intravascular inoculation with strains of high and low invasiveness. Am J Hyg. 1954;60:339–357.

39. Bodian D. Viremia in experimental poliomyelitis. II. Viremia and the mechanism of the “provoking” effect of injections or trauma. Am J Hyg. 1954;60:358–370.

40. Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neural pathways. J Infect Dis. 1992;166:747–752.

41. Bodian D, Howe HA. An experimental study of the role of neurones in the dissemination of poliomyelitis virus in the nervous system. Brain. 1940;63:135.

42. Jubelt B, Gallez-Hawkins G, Narayan O, et al. Pathogenesis of human poliovirus infection in mice. I. Clinical and pathological studies. J Neuropathol Exp Neurol. 1980;39:138–148.

43. Bodian D. Histopathological basis of clinical findings in poliomyelitis. Am J Med. 1949;6:563–578.

44. Hammon WM, Coriell LL, Wehrle PF, et al. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. JAMA. 1953;151:1272–1285.

45. Gelfand HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. III. The serologic response to commercially produced “Salk vaccine” of children totally or partially susceptible to poliovirus infection. Am J Hyg. 1959;70:303–311.

46. Henry JL, Jaikaran ES, Davies JR, et al. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg. 1966;64:105–120.

47. Wehrle PF, Carbonaro O, Day PA, et al. Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics. 1961;27:762–764.

48. Paul JR, Riordan JT, Melnick JL. Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan Eskimos. Am J Hyg. 1951;54:275–285.

49. Ogra PL, Karzon DT, Righthand F. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med. 1968;279:893–900.

50. Ogra PL, Karzon DT. Formation and function of poliovirus antibody in different tissues. Prog Med Virol. 1971;13:157–193.

51. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhanced potency IPV and OPV. J Infect Dis. 1991;163:1–6.

52. Grassly NC, Jafari H, Bahl S, et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis. 2009;200(5):794–801.

53. Nishio O, Ishihara Y, Sakae K, et al. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand. 1984;12:1–10.

54. Horstmann DM, Paul JR. The incubation period in human poliomyelitis and its implications. JAMA. 1947;135:11.

55. Melnick JL, Ledinko N. Social serology: antibody levels in a normal young population during an epidemic of poliomyelitis. Am J Hyg. 1951;54: 354–382.

56. Weinstein L, Shelokov A, Seltser R, et al. A comparison of the clinical features of poliomyelitis in adults and children. N Engl J Med. 1952;246:297–302.

57. Russell WR, Fischer-Williams M. Recovery of muscular strength after poliomyelitis. Lancet. 1954;1:330–333.

58. Voroshilova MK, Chumakov MP. Poliomyelitis-like properties of AB-IV-coxsackie A7 group of viruses. Prog Med Virol. 1959;2:106–170.

59. Grist NR, Bell EJ. Enteroviral etiology of the paralytic poliomyelitis syndrome. Arch Environ Health. 1970;21:382–387.

60. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341:929–935.

61. Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341:936–942.

62. Lee TC, Guo HR, Su HJ, et al. Diseases caused by enterovirus 71 infection. Ped Infect Dis J. 2009;28(10):904–910.

63. Anderson GW, Anderson G, Skaar A, et al. Poliomyelitis in pregnancy. Am J Hyg. 1952;55:127–139.

64. Weinstein L, Aycock WL, Feemster RF. Relation of sex, pregnancy, and menstruation to susceptibility in poliomyelitis. N Engl J Med. 1951;245:54–58.

65. Harjulehto T, Aro T, Hovi T, et al. Congenital malformations and oral poliovirus vaccination during pregnancy. Lancet. 1989;1:771–772.

66. Siegel M, Greenberg M. Poliomyelitis in pregnancy: effect on fetus and newborn infant. J Pediatr. 1956;49:280–288.

67. Davis LE, Bodian D, Price D, et al. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. N Engl J Med. 1977;297:241–245.

68. Wyatt HV. Poliomyelitis in hypogammaglobulinemics. J Infect Dis. 1973;128:802–806.

69. Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med. 1994;11:426,429–430,435–438.

70. Khetsuriani N, Prevots DR, Quick L, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188:1845–1852.

71. Horstmann DM. Acute poliomyelitis. Relation of physical activity at the time of onset to the course of the disease. JAMA. 1950;142:236–241.

72. Russell WR. Paralytic poliomyelitis: the early symptoms and the effect of physical activity on the course of disease. Br Med J. 1949;1:465–471.

73. Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the virulence of murine coxsackievirus B-3 myocardiopathy by exercise. J Exp Med. 1970;131:1121–1136.

74. Greenberg M, Abramson H, Cooper HM, et al. The relation between recent injections and paralytic poliomyelitis in children. Am J Public Health. 1952;42:142–152.

75. Hill AB, Knowelden J. Inoculation and poliomyelitis: a statistical investigation in England and Wales in 1949. Br Med J. 1950;2:1–6.

76. Sutter RW, Patriarca PA, Suleiman AM, et al. Attributable risk of DTP (diphtheria and tetanus toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. J Infect Dis. 1992;165:444–449.

77. Strebel PM, Nedelcu NI, Baughman AL, et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine—a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med. 1995;332:500–506.

78. Paffenbarger RS, Wilson VO. Previous tonsillectomy and current pregnancy as they affect risk of poliomyelitis. Ann N Y Acad Sci. 1955;61: 856–868.

79. Charcot JM. Paralysie essentielle de l’enfance: atrophie musculaire consecutive. Gaz Med (Paris). 1875;4:225–226.

80. Campbell AMG, Williams MB, Pearce J. Late motor neuron degeneration following poliomyelitis. Neurology. 1969;19:1101–1106.

81. Martyn CN, Barker DJP, Osmond C. Motoneuron disease and past poliomyelitis in England and Wales. Lancet. 1988;1:1319–1320.

82. Mulder DW, Rosenbaum RA, Layton DD. Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis? Mayo Clin Proc. 1972;47:756–761.

83. Armon C, Jasper RD, Windebank AJ, et al. How frequently does classic amyotrophic lateral sclerosis develop in survivors of poliomyelitis? Neurology. 1990;40:172–174.

84. Dalakas MC, Elder G, Hallet M, et al. A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms. N Engl J Med. 1986;314:959–963.

85. Currie DM, Gershkoff AM, Cifu DX. Geriatric rehabilitation 3: mid- and late-life effects of early-life disabilities. Arch Phys Med Rehabil. 1993;74(suppl):S413–S416.

86. Trojan DA, Cashman NR, Shapiro S, et al. Predictive factors for post-poliomyelitis syndrome. Arch Phys Med Rehabil. 1994;75:770–777.

87. Trojan DA, Gendron D, Cashman NR. Stimulation frequency-dependent neuromuscular junction transmission defects in patients with prior poliomyelitis. J Neurol Sci. 1993;118:150–157.

88. Birk TJ. Poliomyelitis and the post-polio syndrome: exercise capacities and adapation—current research, future directions, and widespread applicability. Med Sci Sports Exerc. 1993;25:466–472.

89. Dalakas MC, Sever JL, Madden DL, et al. Late postpoliomyelitis muscular atrophy: clinical, virologic, and immunologic studies. Rev Infect Dis. 1984;6(2):S562–S567.

90. Lange DJ, Smith T, Lovelace RE. Postpolio muscular atrophy: diagnostic utility of macroelectromyography. Arch Neurol. 1989;46:502–506.

91. Ryniewicz B, Rowinska-Marcinska K, Emeryk B, et al. Disintegration of the motor unit in post-polio syndrome. Part I. Electrophysiological findings in patients after poliomyelitis. Electromyogr Clin Neurophysiol. 1990;30:423–427.

92. Jubelt B, Drucker J. Post-polio syndrome: an update. Sem Neurol. 1993;13:283–290.

93. Munsat TL. Poliomyelitis—new problems with an old disease. N Engl J Med. 1991;324:1206–1207.

94. Ramlow J, Alexander M, LaPorte R, et al. Epidemiology of the post-polio syndrome. Am J Epidemiol. 1992;136:769–786.

95. Windebank AJ, Litchy WJ, Daube JR, et al. Late effects of paralytic poliomyelitis in Olmsted County, Minnesota. Neurology. 1991;41: 501–507.

96. Jubelt B, Cashman NR. Neurological manifestations of post-polio syndrome. Crit Rev Neurobiol. 1987;3:199–220.

97. Dawson RB. Immune responses in the post-polio syndrome [letter]. N Engl J Med. 1992;326:641–642.

98. Dalakas MC, Sever JL, Fletcher M, et al. Neuromuscular symptoms in patients with old poliomyelitis: clinical, virological and immunologic studies. In: Halstead LS, Weichers DO, eds. Late Effects of Poliomyelitis. Miami, FL: Symposia Foundation; 1985:73–89.

99. Sharief MK, Hentges R, Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N Engl J Med. 1991;325:749–755.

100. Stone R. Post-polio syndrome: remembrance of viruses past. Science. 1994;264:909.

101. Rosenberg LT, Hamparian VV. Immune responses in the post-polio syndrome [letter]. N Engl J Med. 1992;326:640–642.

102. Salazar-Grueso EF, Grimaldi LME, Roos RP, et al. Isoelectric focusing studies of serum and cerebrospinal fluid in patients with antecedent poliomyelitis. Ann Neurol. 1989;26:709–713.

103. Agre JC, Rodriquez AA. Neuromuscular function in polio survivors. Orthopedics. 1991;14:1343–1347.

104. Berlly MH, Strauser WW, Hall KM. Fatigue in post-polio syndrome. Arch Phys Med Rehabil. 1991;72:115–118.

105. Packer TL, Martins I, Krefting L, et al. Activity and post-polio fatigue. Orthopedics. 1991;14:1223–1226.

106. Sharma KR, Kent-Braun J, Mynhier MA, et al. Excessive muscular fatigue in the postpoliomyelitis syndrome. Neurology. 1994;44:642–664.

107. Gyermek L. Increased potency of nondepolarizing relaxants after poliomyelitis. J Clin Pharmacol. 1990;30:170–173.

108. Louhan JA. Epidemic poliomyelitis: some pathological observations on human material. Arch Pathol. 1946;42:245–260.

109. Bodian D. Poliomyelitis: neuropathologic observations in relation to motor symptoms. JAMA. 1947;134:1148–1154.

110. Bruno RL, Cohen JM, Galaski T, et al. The neuroanatomy of post-polio fatigue. Arch Phys Med Rehabil. 1994;75:498–504.

111. Bruno RL. Post-polio sequelae: research and treatment in the second decade [editorial]. Orthopedics. 1991;14:1169–1170.

112. Bruno RL, Frick NM, Cohen J. Polioencephalitis, stress, and the etiology of post-polio sequelae. Orthopedics. 1991;14:1269–1276.

113. Sonies BC, Dalakas MC. Dysphagia in patients with the post-polio syndrome. N Engl J Med. 1991;324:1162–1167.

114. Bach JR, Alba AS. Pulmonary dysfunction and sleep disordered breathing as post-polio sequelae: evaluation and management. Orthopedics. 1991;14:1329–1337.

115. Dean E, Ross H, Road JD, et al. Pulmonary function in individuals with a history of poliomyelitis. Chest. 1991;100:118–123.

116. Bruno RL, Galski T, DeLuca J. The neuropsychology of post-polio fatigue. Arch Phys Med Rehabil. 1993;74(suppl):S413–S416.

117. Emeryk B, Rowinska-Marcinska K, Ryniewicz B, et al. Disintegration of the motor unit in post-polio syndrome. Part II. Electrophysiological findings in patients with post-polio syndrome. Electromyogr Clin Neurophysiol. 1990;30:451–458.

118. Clark K, Dinsmore DO, Grafman J, et al. A personality profile of patients diagnosed with post-polio syndrome. Neurology. 1994;44:1809–1811.

119. Cashman NR, Maselli R, Wollman RL. Late denervation in patients with antecedent paralytic poliomyelitis. N Engl J Med. 1987;317:7–12.

120. Jones DR, Speier J, Canine K, et al. Cardiorespiratory responses to aerobic training by patients with postpoliomyelitis sequelae. JAMA. 1989;261:3255–3258.

121. Young GR. Energy conservation, occupational therapy, and the treatment of post-polio sequelae. Orthopedics. 1991;14:1233–1239.

122. Peach PE, Olejnik S. Effect of treatment and noncompliance on post-polio sequelae. Orthopedics. 1991;14:1199–1203.

123. Fillyaw MJ, Badger GJ, Goodwin GD, et al. The effects of long-term non-fatiguing exercise in subjects with postpolio syndrome. Orthopedics. 1991;14:1253–1256.

124. Einarsson G. Muscle conditioning in late poliomyelitis. Arch Phys Med Rehabil. 1991;72:11–14.

125. Milner-Brown HS. Muscle strengthening in a post-polio subject through a high-resistance weight-training program. Arch Phys Med Rehabil. 1993;74:1165–1167.

126. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep. 2009;58:829–830.

127. McBean AM, Thoms ML, Albrecht P, et al. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am J Epidemiol. 1988;128:615–628.

128. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience of Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J. 1997;16:312–322.

129. Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet. 1988;1: 897–899.

130. Bijkerk H. Poliomyelitis epidemic in the Netherlands. Dev Biol Stand. 1979;43:195–206.

131. Stickle G. Observed and expected poliomyelitis in the United States, 1958–1961. Am J Public Health. 1964;54:1222–1229.

132. Gelfand HM, Potash L, LeBlanc DR, et al. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. JAMA. 1959;170: 2039–2048.

133. Wehrle PF, Reichert R, Carbonaro O, et al. Influence of prior active immunization on the presence of poliomyelitis virus in the pharynx and stools of family contacts of patients with paralytic poliomyelitis. Pediatrics. 1958;21:353–361.

134. Robertson HE, Acker MS, Dillenberg HO, et al. Community-wide use of a “balanced” trivalent oral poliovirus vaccine (Sabin). Can J Public Health. 1962;53:179–191.

135. Cohen-Abbo A, Culley BS, Reed GW, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Ped Infect Dis J. 1995;14:100–106.

136. Hardy GE, Hopkins CC, Linneman CC, et al. Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. Pediatrics. 1970;45:444–448.

137. Krugman RD, Hardy GE, Sellers C. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics. 1977;60:80–82.

138. Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis. 1984;6(2):S361–S368.

139. Ghendon YUZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin’s strains) in person after naturally and experimentally acquired immunity. Acta Virol (Praha). 1961;5: 265–273.

140. Expanded Programme on Immunization. Poliomyelitis surveillance and vaccine efficacy. Wkly Epidemiol Rec. 1988;63:249–251.

141. Dong DX, Hu XM, Liu WJ, et al. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). Bull World Health Organ. 1986;64:853–860.

142. John TJ, Jayabal P. Oral polio vaccination of children in the tropics: I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol. 1972;96:263–269.

143. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev Infect Dis. 1991;13:926–939.

144. Jenkins HE, Aylward RB, Gasasira A, et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med. 2008;359(16):1666–1674.

145. Sutter RW, Patriarca PA, Brogan S, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet. 1991;338:715–720.

146. de Brito Bastos NC, de Carvalho ES, Schatzmayr H, et al. Antipoliomyelitis program in Brazil: a serologic study of immunity. Bull Pan Am Health Organ. 1974;8:54–65.

147. Lasch EE, Abed Y, Abdulla K, et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis. 1984;6(2):467–470.

148. Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Ped Infect Dis J. 1996;15:204–209.

149. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Effect of diarrhea on seroconversion to oral poliovirus vaccine. Paper presented at: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11–14, 1992; Anaheim, CA.

150. Caceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis. 2001;33:531–541.

151. el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359:1655–1665.

152. Waggie Z, Geldenhuys H, Sutter RW, et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis. 2012;205:228–236.

153. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA. 1996;275:1639–1645.

154. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010;23:213–228.

155. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14:568–579.

156. Wyatt HV. Risk of live poliovirus in immunodeficient children. J Pediatr. 1975;87:152–153.

157. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36:2893–2899.

158. Le Menach A, Llosa AE, Mouniaman-Nara I, et al. Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010–February 2011. Emerg Infect Dis. 2011;17(8):1506–1509.

159. Henderson RH. The Expanded Programme on Immunization of the World Health Organization. Rev Infect Dis. 1984;6(2):475–479.

160. Ofusu-Amaah S. The challenge of poliomyelitis in tropical Africa. Rev Infect Dis. 1984;6(2):318–320.

161. Rockefeller Foundation. Protecting the world’s children: vaccines and immunization. Paper presented at: Bellagio Conference; March 13–15, 1984; Bellagio, Italy.

162. Horstmann DM. Preface to the 1983 International Symposium on Poliomyelitis Control. Rev Infect Dis. 1984;6(suppl 2):S301.

163. Hull HF, Ward NA, Hull BP, et al. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994;343:1331–1337.

164. Wright PF, Kim-Farley RJ, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med. 1991;325:1774–1779.

165. World Health Organization. Global eradication of poliomyelitis by the year 2000. Wkly Epidemiol Rec. 1988;63:161–162.

166. Aylward B, Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine. 2011;29(suppl 4):D80–D85.

167. Richardson G, Linkins R, Eames M, et al. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bull World Heath Organ. 1995;73:769–777.

168. Cruz RR. Cuba: mass polio vaccination program, 1962–1982. Rev Infect Dis. 1984;6(2):408–412.

169. Risi JB. The control of poliomyelitis in Brazil. Rev Infect Dis. 1984;6(2): 400–403.

170. Abraham T. Polio eradication: a complex end game. Br Med J. 2012;344: e2398.

171. Centers for Disease Control and Prevention. Progress toward the global interruption of wild poliovirus type 2 transmission, 1999. MMWR Morb Mortal Wkly Rep. 1999;48:736–747.

172. Centers for Disease Control and Prevention. Progress towards global eradication of poliomyelitis, 2002. MMWR Morb Mortal Wkly Rep. 2003; 52:366–369.

173. Modlin JF. The bumpy road to polio eradication. N Engl J Med. 2010; 362:2346–2349.

174. Patriarca PA. Research and development and the polio eradication initiative: too much, too soon . . . too little, too late? Clin Infect Dis. 2012;55:1307–1311.

175. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356–359.

176. Centers for Disease Control and Prevention. Outbreak of poliomyelitis—Dominican Republic and Haiti, 2000. MMWR Morb Mortal Wkly Rep. 2000;49:1094.

177. Centers for Disease Control and Prevention. Circulation of a type 2 vaccine-derived poliovirus—Egypt, 1982–1993. MMWR Morb Mortal Wkly Rep. 2001;50:41–42,51.

178. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol. 2005;59:587–635.

179. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1002–1006.

180. Dowdle WR, de Gourville E, Kew OM, et al. Polio eradication: the OPV paradox. Rev Med Virol. 2003;13:277–291.

181. Nathanson N, Fine P. Poliomyelitis eradication—a dangerous endgame. Science. 2002;296:269–270.

182. Sutter RW, Suleiman AJ, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. N Engl J Med. 2000;343(11):767–773.

183. World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec. 2003;78:241–250.

184. Asturias EJ, Dueger EL, Omer SB, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis. 2007;196:692–698.

185. Dayan GH, Thorley M, Yamamura Y, et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis. 2007;195:12–20.

186. du Chatelet IP, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine. 2003;21: 1710–1718.

187. Lasch EE, Abed Y, Marcus O, et al. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country—five years after. Develop Biol Stand. 1986;65:137–143.

188. Morinere BJ, van Loon FPL, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 1993;341:1545–1550.

189. Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. “Endgame” issues for the global polio eradication initiative. Clin Infect Dis. 2002;34:72–77.



If you find an error or have any questions, please email us at admin@doctorlib.info. Thank you!